One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near? (Q36418818)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near? |
scientific article |
Statements
1 reference
One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near? (English)
1 reference
Christina Schmitt
1 reference
Alexander Grundt
1 reference
Christian Buchholtz
1 reference
Lars Scheuer
1 reference
Axel Benner
1 reference
Manfred Hensel
1 reference
Anthony D Ho
1 reference
Eugen Leo
1 reference
10 March 2006
1 reference
1 reference
Identifiers
1 reference